
AnaptysBio (ANAB) Stock Forecast & Price Target
AnaptysBio (ANAB) Analyst Ratings
Bulls say
AnaptysBio is a promising investment for several reasons. The company has entered a lucrative deal to monetize a portion of its Jemperli revenue, providing significant cash flow to fund pipeline development. Additionally, Anaptys is focused on growing its royalty revenue through its drug imsidolimab, which has shown potential for treating multiple inflammatory conditions and has promising results in Phase 3 trials for colon cancer and GPP. Despite a legal dispute with GSK/Tesaro, Anaptys is still expected to be a strong investment with its growth prospects and potential for significant royalties.
Bears say
AnaptysBio is an innovative biotechnology company with promising antibody product candidates in clinical development for unmet medical needs, specifically in the areas of inflammation and immuno-oncology. Their collaboration with Tesaro provides potential for milestone payments and royalties, and their financial backing from Sagard Holdings and Celgene provides stability. The recent court ruling in their favor and potential for upsides in royalty rates further solidifies AnaptysBio's outlook.
This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.
AnaptysBio (ANAB) Analyst Forecast & Price Prediction
Start investing in AnaptysBio (ANAB)
Order type
Buy in
Order amount
Est. shares
0 shares